The estimated Net Worth of James Kihara is at least $407 ezer dollars as of 1 May 2024. Mr. Kihara owns over 2,596 units of Acadia Pharmaceuticals Inc stock worth over $250,351 and over the last 4 years he sold ACAD stock worth over $156,660. In addition, he makes $0 as Principal Accounting Officer at Acadia Pharmaceuticals Inc.
James has made over 13 trades of the Acadia Pharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 2,596 units of ACAD stock worth $41,406 on 1 May 2024.
The largest trade he's ever made was exercising 11,894 units of Acadia Pharmaceuticals Inc stock on 17 May 2023 worth over $189,709. On average, James trades about 2,053 units every 44 days since 2021. As of 1 May 2024 he still owns at least 15,696 units of Acadia Pharmaceuticals Inc stock.
You can see the complete history of Mr. Kihara stock trades at the bottom of the page.
James Kihara serves as Principal Accounting Officer of the Company. He has been with the Company since March 2020. Prior to joining the Company, Mr. Kihara worked at Cubic Corporation, an information technology and services firm, from November 2012 to March 2020, most recently serving as chief financial officer of the Cubic Mission Solutions business segment. Prior to Cubic Corporation, Mr. Kihara was employed by Ernst & Young LLP, a multinational professional services firm, and served as a Senior Manager of Assurance Services. Mr. Kihara earned a bachelor’s degree in Business Administration (Accounting) from San Diego State University and is a certified public accountant in the State of California.
James Kihara is 40, he's been the Principal Accounting Officer of Acadia Pharmaceuticals Inc since 2020. There are 15 older and no younger executives at Acadia Pharmaceuticals Inc. The oldest executive at Acadia Pharmaceuticals Inc is Edmund Harrigan, 67, who is the Independent Director.
James's mailing address filed with the SEC is C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO, CA, 92130.
Over the last 20 years, insiders at Acadia Pharmaceuticals Inc have traded over $21,409,958 worth of Acadia Pharmaceuticals Inc stock and bought 29,279,665 units worth $647,484,672 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B... és Carl L Gordon. On average, Acadia Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $2,248,934. The most recent stock trade was executed by Mark C. Schneyer on 16 August 2024, trading 9,733 units of ACAD stock currently worth $148,720.
acadia pharmaceuticals (nasdaq: acad) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (cns) disorders. all of acadia's product candidates emanate from internal discoveries. we believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. acadia’s history is rooted in science and strong leadership in cns research. our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. acadia is headquartered in san diego. the city represents the second largest biotechnology industry cluster in the united states, home to over 400 companies, as well as the salk institute for biological studies
Acadia Pharmaceuticals Inc executives and other stock owners filed with the SEC include: